← Back
M 10b5-1 Plan

$ Value

$18.0M

Shares

150,000

Price

$120

Filed

Nov 3

Insider

Name

Chapman Steven Leonard

Title

CEO AND PRESIDENT

CIK

0001711968

Roles

Director Officer

Transaction Details

Transaction Date

2025-11-03

Code

M

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

305,519

Footnotes

The sale of shares on this form was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024. The sale of 150,000 of these shares was governed by the initial plan and not altered by the subsequently amendment. | The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.28 to $198.27 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.44 to $199.43 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.51 to $200.00 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | The option shares are fully exercisable. | On January 22, 2021, the Reporting Person was granted performance-based options which vest in tranches upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria. The performance thresholds were certified on June 28, 2024, March 28, 2025 and September 28, 2025, resulting in the performance-based option being fully vested as of the last performance threshold date.

Filing Info

Accession No.

0001711968-25-000011

Form Type

4

Issuer CIK

0001604821

Chapman Steven Leonard's History

Date Ticker Type Value
2026-03-10 NTRA $1.1M
2026-03-09 NTRA A
2026-03-02 NTRA $223K
2026-03-02 NTRA $493K
2026-03-02 NTRA $73K
2026-02-27 NTRA A
2026-02-03 NTRA $1.1M
2026-02-02 NTRA $1.5M
2026-02-02 NTRA $9.6M
2026-02-02 NTRA $4.6M

Other Insiders at NTRA (90d)

Insider Bought Sold Last
BOTHA ROELOF 2026-01-30
ROSENMAN HERM 2026-01-30
Williams Brinkley Ruth 2026-01-30
Rabinowitz Matthew
EXECUTIVE CHAIRMAN
$38.3M 2026-04-06
Sheena Jonathan $2.4M 2026-04-17
Baynes Roy D. 2026-01-30
Brophy Michael Burkes
CHIEF FINANCIAL OFFICER
$2.9M 2026-03-10
Marcus Gail Boxer 2026-01-30
Chapman Steven Leonard
CEO AND PRESIDENT
$24.1M 2026-03-10
Bertagnolli Monica 2026-01-30
Chapman Rowan E $23K 2026-03-13
RABINOWITZ DANIEL
SEC. AND CHIEF LEGAL OFFICER
$4.5M 2026-04-01
Moshkevich Solomon
PRESIDENT, CLINICALDIAGNOSTICS
$3.0M 2026-04-01
Fesko John
PRESIDENT, CHIEF BUS. OFFICER
$1.4M 2026-03-10